First‑Line Antibiotic Recommendations for Pediatric Community‑Acquired Pneumonia

Outpatient Management – Preschool Children (< 5 years)

• Amoxicillin 90 mg/kg/day divided twice daily for 5–7 days is the recommended first‑line therapy for presumed bacterial pneumonia in otherwise healthy out‑patients. (Clinical Infectious Diseases guideline) 1
• If the child is not fully immunized against Haemophilus influenzae type b or Streptococcus pneumoniae, use amoxicillin‑clavulanate with the amoxicillin component dosed at 90 mg/kg/day divided twice daily. (Clinical Infectious Diseases guideline) 1
• Azithromycin (10 mg/kg on day 1, then 5 mg/kg once daily on days 2–5) is recommended for the rare cases of presumed atypical pneumonia in this age group. (Clinical Infectious Diseases guideline) 1
• Alternative macrolide regimens for atypical pneumonia include clarithromycin 15 mg/kg/day divided twice daily for 7–14 days or erythromycin 40 mg/kg/day divided four times daily. (Clinical Infectious Diseases guideline) 1

Outpatient Management – School‑Age Children (≥ 5 years)

• Amoxicillin 90 mg/kg/day divided twice daily (maximum 4 g/day) for 5–7 days remains the first‑line agent for presumed bacterial pneumonia. (Clinical Infectious Diseases guideline) 1
• When clinical features do not clearly differentiate bacterial from atypical pneumonia, add azithromycin (10 mg/kg on day 1, then 5 mg/kg daily on days 2–5; max 500 mg day 1, 250 mg thereafter). (Clinical Infectious Diseases guideline) 1
• Atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae) are more common in school‑age children. (Praxis Medical Insights) 2
• For isolated atypical pneumonia, azithromycin monotherapy with the same dosing is recommended. (Clinical Infectious Diseases guideline) 1
• Alternative agents for atypical pneumonia include clarithromycin 15 mg/kg/day divided twice daily (maximum 1 g/day) or doxycycline in children older than 7 years. (Clinical Infectious Diseases guideline) 1

Inpatient Management – Low‑Risk, Fully Immunized Children

• Ampicillin 150–200 mg/kg/day intravenously every 6 hours or Penicillin G 200,000–250,000 U/kg/day intravenously every 4–6 hours is the preferred empiric regimen.** (Clinical Infectious Diseases guideline) 1
• Ceftriaxone 50–100 mg/kg/day intravenously once daily (or every 12–24 hours) may be used as an alternative. (Clinical Infectious Diseases guideline) 1

Inpatient Management – Not Fully Immunized or High‑Risk Children

• Ceftriaxone 50–100 mg/kg/day intravenously or Cefotaxime 150 mg/kg/day intravenously every 8 hours is recommended to cover penicillin‑resistant S. pneumoniae and β‑lactamase‑producing H. influenzae.** (Clinical Infectious Diseases guideline) 1

Inpatient Management – Suspected MRSA (Severe Pneumonia, Necrotizing Features, Empyema, Recent Influenza)

• Add vancomycin 40–60 mg/kg/day intravenously every 6–8 hours or clindamycin 40 mg/kg/day intravenously every 6 hours to the β‑lactam regimen.** (Clinical Infectious Diseases guideline) 1
• Failure to consider MRSA in severe presentations is a critical pitfall. (Praxis Medical Insights) 3

Inpatient Management – Hospitalized Atypical Pneumonia

• Azithromycin 10 mg/kg intravenously on days 1 and 2, then transition to oral therapy, is the preferred regimen. (Clinical Infectious Diseases guideline) 1
• Erythromycin lactobionate 20 mg/kg/day intravenously every 6 hours is an alternative. (Praxis Medical Insights) 3

Penicillin‑Allergy Management

• For non‑severe allergic reactions (e.g., rash without anaphylaxis), oral cephalosporins such as cefpodoxime, cefprozil, or cefuroxime can be used under medical supervision; cross‑reactivity risk is low (1–3%). (Praxis Medical Insights) 3
• Azithromycin (10 mg/kg day 1, then 5 mg/kg daily days 2–5; max 500 mg/500 mg) is a safe β‑lactam‑free alternative. (Praxis Medical Insights) 3
• For severe allergic reactions (anaphylaxis, angioedema), levofloxacin is the preferred alternative:
  
  • Children 6 months–5 years: 16–20 mg/kg/day divided twice daily.
  • Children 5–16 years: 8–10 mg/kg once daily (maximum 750 mg/day).** (Praxis Medical Insights) 3
• Linezolid may be used as an alternative: 30 mg/kg/day divided three times daily for children < 12 years, or 20 mg/kg/day divided twice daily for children ≥ 12 years.** (Praxis Medical Insights) 3

Clinical Monitoring and Treatment Failure

• Children receiving appropriate therapy should show clinical improvement (reduced fever, better respiratory effort, improved oral intake) within 48–72 hours. (Clinical Infectious Diseases guideline) 1
• If no improvement or deterioration occurs within 48–72 hours:
  
  • Obtain blood cultures and consider pleural‑fluid sampling if an effusion is present. (Praxis Medical Insights) 3
  • Reassess for complications such as parapneumonic effusion, empyema, necrotizing pneumonia, or lung abscess. (Clinical Infectious Diseases guideline) 1
  • Consider resistant organisms (e.g., MRSA, penicillin‑resistant S. pneumoniae) or alternative diagnoses. (Praxis Medical Insights) 3
  • Escalate to intravenous antibiotics if the patient is still outpatient, or broaden coverage if already hospitalized. (Praxis Medical Insights) 3

Critical Pitfalls to Avoid

• Do not use macrolides as first‑line monotherapy for presumed bacterial pneumonia in children < 5 years; they lack reliable activity against S. pneumoniae. (Praxis Medical Insights) 3
• Do not underdose amoxicillin; the high dose of 90 mg/kg/day (not 40–45 mg/kg/day) is required to overcome pneumococcal resistance. (Praxis Medical Insights) 3
• Do not use cefixime or cefdinir as first‑line empiric therapy; they provide inadequate pneumococcal coverage compared with high‑dose amoxicillin. (Praxis Medical Insights) 3
• Do not delay adding vancomycin or clindamycin in severe pneumonia with necrotizing features or empyema, as MRSA is a life‑threatening possibility. (Praxis Medical Insights) 3
• Do not continue inadequate therapy beyond 48–72 hours without reassessment; prompt escalation prevents treatment failure. (Clinical Infectious Diseases guideline) 1

Azithromycin Preferred Over Clarithromycin for Pediatric Community‑Acquired Pneumonia When a Macrolide Is Indicated

Clinical Efficacy

• Azithromycin and clarithromycin achieve comparable clinical cure rates in children with community‑acquired pneumonia when a macrolide is appropriate, but azithromycin is favored because it is better tolerated, requires a shorter course (3–5 days versus 7–14 days), and is given once daily, which improves adherence. 4

Indications for Macrolide Use

• In children ≥ 5 years with suspected atypical pneumonia (e.g., Mycoplasma pneumoniae or Chlamydophila pneumoniae), macrolide monotherapy is recommended because atypical pathogens are more common in this age group. 4

Recommended Azithromycin Dosing (British Thoracic Society)

• The loading dose on day 1 is essential to achieve adequate tissue concentrations; under‑dosing may reduce efficacy. 4

Guideline Evidence Supporting Azithromycin Preference (British Thoracic Society)

• The Society’s guideline found no difference in efficacy between erythromycin (10 days) and clarithromycin (10 days), nor between azithromycin (3‑5 days) and erythromycin (7 days). This demonstrates that a shorter azithromycin regimen is as effective as longer macrolide courses. 4, 5, 6
• A shorter treatment course (3‑5 days) improves patient compliance without compromising clinical outcomes compared with the traditional 7‑14 day regimens of clarithromycin or erythromycin. 4

Duration Recommendations

• For uncomplicated pediatric pneumonia, azithromycin should not be extended beyond 5 days; studies show 3‑5 day courses are equally effective as longer courses. 4

Management of Community‑Acquired Pneumonia in Previously Healthy Adolescents

First‑Line Outpatient Antibiotic Therapy

• High‑dose oral amoxicillin (90 mg/kg/day divided twice daily, maximum 4 g/day) for 5–7 days is the definitive first‑line regimen for an otherwise healthy adolescent with community‑acquired pneumonia, providing optimal coverage of Streptococcus pneumoniae and overcoming common penicillin resistance. 7
• When atypical pathogens cannot be excluded, add azithromycin 10 mg/kg on day 1 (max 500 mg) then 5 mg/kg daily on days 2–5 (max 250 mg/day). This combination addresses Mycoplasma pneumoniae and Chlamydophila pneumoniae. 7
• Alternative macrolide options include clarithromycin 15 mg/kg/day divided twice daily for 7–14 days (max 1 g/day) or doxycycline 200 mg once daily in patients older than 7 years. 7

Hospitalization Criteria

Major (any one mandates ICU/continuous monitoring)

• Need for invasive mechanical ventilation. 7, 8
• Fluid‑refractory shock. 7, 8
• Acute requirement for non‑invasive positive‑pressure ventilation (CPAP or BiPAP). 7, 8
• Hypoxemia requiring FiO₂ > 0.50 or oxygen delivery not feasible on a general ward. 7, 8
• Pulse oximetry < 92 % on inspired O₂ ≥ 0.50. 8
• Altered mental status secondary to hypercarbia or hypoxemia. 8

Minor (presence of two or more warrants admission)

• Respiratory rate exceeding WHO age‑specific thresholds. 7
• Episodes of apnea. 7
• Increased work of breathing (retractions, dyspnea, nasal flaring, grunting). 7
• PaO₂/FiO₂ ratio < 250. 7
• Multilobar infiltrates on imaging. 7
• Presence of pleural effusion. 7
• Hypotension. 7
• Unexplained metabolic acidosis. 7

Additional Indicators

• Significant respiratory distress. 7
• Failure to improve or clinical deterioration within 48–72 hours of appropriate outpatient therapy. 7, 8

Management of Penicillin Allergy

• Severe IgE‑mediated reactions (anaphylaxis, angioedema): levofloxacin 8–10 mg/kg once daily (maximum 750 mg) is the preferred β‑lactam‑free alternative; linezolid 20 mg/kg/day divided twice daily (for children ≥ 12 years) is an additional option. 9

Inpatient Antibiotic Regimens

Fully Immunized, Low‑Risk Patients

• Preferred: ampicillin 150–200 mg/kg/day IV every 6 hours or penicillin G 200,000–250,000 U/kg/day IV every 4–6 hours. 9
• Acceptable alternative: ceftriaxone 50–100 mg/kg/day IV once daily (or every 12–24 hours). 9

Not Fully Immunized or High‑Risk Patients

• Ceftriaxone 50–100 mg/kg/day IV or cefotaxime 150 mg/kg/day IV every 8 hours to cover penicillin‑resistant S. pneumoniae and β‑lactamase‑producing H. influenzae. 9

Suspected MRSA (e.g., necrotizing pneumonia, empyema, recent influenza)

• Add vancomycin 40–60 mg/kg/day IV every 6–8 hours or clindamycin 40 mg/kg/day IV every 6 hours to the β‑lactam backbone. 9

Clinical Monitoring and Treatment Failure

• Expected response: clinical improvement (defervescence, reduced work of breathing, better oral intake) should be evident within 48–72 hours of initiating appropriate therapy. 7
• If no improvement/deterioration within 48–72 hours: obtain blood cultures and, if a pleural effusion is present, consider pleural‑fluid sampling. 8
• Re‑evaluate for complications such as parapneumonic effusion, empyema, necrotizing pneumonia, or lung abscess. 7
• Consider resistant organisms (MRSA, penicillin‑resistant S. pneumoniae) or alternative diagnoses and broaden antimicrobial coverage as needed. 8

Diagnostic Testing Recommendations

• Outpatient setting: routine chest radiography is not required for well‑appearing patients; pulse oximetry should be performed in all suspected cases to guide disposition. 7
• Outpatient blood cultures: not routinely indicated in nontoxic, fully immunized adolescents. 8
• Chest radiograph indications: obtain when diagnosis is uncertain, hypoxemia or significant respiratory distress is present, or the patient fails to improve within 48–72 hours. 7
• Inpatient setting: chest radiographs are obtained for all hospitalized patients to document infiltrates and detect complications; blood cultures are obtained in moderate to severe cases. 7, 8

Critical Pitfalls (Evidence‑Based Alerts)

• Underdosing amoxicillin (using 40–45 mg/kg/day) fails to overcome pneumococcal resistance; the high‑dose regimen is essential. 7
• Using macrolides as monotherapy for presumed bacterial pneumonia is inappropriate because of unreliable activity against S. pneumoniae. 7
• Delaying addition of vancomycin or clindamycin in severe pneumonia with necrotizing features or empyema can be fatal due to MRSA. 7
• Continuing inadequate therapy beyond 48–72 hours without reassessment increases risk of treatment failure; prompt escalation is recommended. 7

Strength of evidence: not explicitly graded in the source; recommendations are based on consensus and clinical data from the cited guideline.